Ozempic® and nausea

Nausea in the US safety table

Section 6.1 of the Ozempic® label builds its main safety table from two placebo-controlled studies in adults with type 2 diabetes: one where Ozempic® was the only diabetes medicine and one where it was added to basal insulin. Together they exposed 521 people to Ozempic® for an average of about 33 weeks. Nausea is the first and largest row ^[1].

The placebo column matters. Some people felt sick without any active medicine, so the gap between the columns tells you more than either number alone. Ozempic® tablets are a separate product with their own prescribing information shared with Rybelsus®, so their figures are not covered here ^[9].

What the European and Canadian documents add

The European product information sorts side effects into frequency classes. Nausea and diarrhoea are the two stomach reactions it places in the top class, very common, meaning at least 1 person in 10. Its pool of eight phase 3a trials, with 4,792 people exposed to semaglutide up to 1 mg, gives nausea in 17% on 0.5 mg and 19.9% on 1 mg; it says the stomach events were mostly mild to moderate, short-lived and most often reported in the first months ^[2].

Canada’s product monograph uses a pool of seven placebo- or active-controlled trials and compares Ozempic® with a mixed comparator group that includes placebo and other diabetes medicines. Investigators graded stomach reactions as mild far more often than severe: mild in 38.8% and 36.5% of cases on the two doses, severe in 1.7% and 1.8% ^[3].

When it tends to arrive, and how often people stopped

All three documents tie nausea to the start of treatment and to dose increases. The US label says most reports of nausea, vomiting and diarrhea came during dose escalation; the European text says stomach events were most frequent in the first months; the manufacturer’s patient page says these side effects were reported more often when starting Ozempic® or raising the dose ^[1][2][4].

The US label gives a stop rate for the whole stomach and bowel group rather than nausea alone: 3.1% on 0.5 mg and 3.8% on 1 mg left treatment for these reactions, against 0.4% on placebo. In a 40-week trial of 1 mg against 2 mg, stomach and bowel reactions overall were slightly more frequent on 2 mg (34% versus 30.8%), while Europe notes that nausea itself occurred in similar proportions on the two doses ^[1][2].

What studies of semaglutide report

Many people with type 2 diabetes take metformin as well, so researchers checked whether combining it with a GLP-1 medicine made the early weeks harder. Across four large trials of liraglutide and semaglutide with 16,996 participants, 76% of whom took metformin, it did not: metformin use did not increase the share who developed stomach side effects or how severe they were during the start-up period. This was a post hoc analysis, meaning it looked back at data collected for other purposes ^[5].

Outside trials, nine real-world studies pooled 3,505 adults with type 2 diabetes using weekly semaglutide for about 30 weeks. Adverse events of the stomach and bowel type were reported by 16.3% of them, and 5.1% stopped because of an adverse event of any kind. These studies describe what was reported among people already using the medicine, so they cannot show how much of it the medicine itself caused ^[6].

Why it may happen

What the label supports: semaglutide’s glucose-lowering action involves a minor delay in stomach emptying in the early period after a meal, and the European text lists delayed gastric emptying as an uncommon reaction in its own right ^[1][2].

What is proposed but not measured in these documents: none of them says that slower emptying is what causes the nausea. A meta-analysis of GLP-1 medicines as a class measured the delay with a scan that tracks a solid meal, and found the stomach took about 36 minutes longer to half-empty than on placebo; a test that reflects liquid emptying showed no clear delay. It did not test whether the delay predicted nausea ^[7].

General medical background: MedlinePlus lists slow stomach emptying among common causes of nausea and names the glutide family of diabetes and obesity medicines among medicines that can bring it on ^[8].

Other possible causes

Feeling sick on Ozempic® is not always the medicine. MedlinePlus lists stomach infections, food poisoning, reflux, migraine, pregnancy, motion sickness, severe pain such as from kidney stones, heavy cannabis use and other medicines. It also names conditions in which nausea can be an early sign of something more serious, including appendicitis, a blocked bowel and stomach ulcers ^[8].

Within the Ozempic® label, nausea also appears inside warnings that are not ordinary side effects: pancreatitis, gallbladder disease and, in people taking insulin or a sulfonylurea, low blood sugar, whose listed signs include sweating, shakiness and hunger ^[1]. That is why the company nausea keeps matters as much as the nausea.

What may help, according to the sources

The Medication Guide’s practical point is about fluids: drinking fluids helps lower the chance of dehydration ^[1]. Novo Nordisk’s Ozempic® patient page goes further with general tips for nausea in the early weeks or after a dose increase ^[4].

• Choose bland, low-fat foods such as crackers, toast and rice, and foods that contain water, such as soups and gelatin; the page adds that this kind of diet is not meant for more than a couple of days ^[4].
• Avoid fried, greasy or sweet foods, eat more slowly and do not lie down straight after eating ^[4].
• Go outside for fresh air and try clear or ice-cold drinks ^[4].
• Follow the dose escalation schedule your prescriber gives you; the patient page presents it as a way to lower the risk of these common side effects ^[4].
• Anti-nausea medicines, including ones sold without a prescription, are a question for your prescriber or pharmacist. The label notes that Ozempic® slows stomach emptying and advises caution with medicines taken by mouth ^[1].

Details worth writing down

A useful note says how many days after the injection the nausea started, how long it lasted, whether it followed a meal and what the meal was, whether you vomited and roughly how much you managed to drink. Mark whether it was the first week on a new dose, because that is the window all three official documents point to.

Over a few weeks, notes like these show whether nausea clusters on certain days, follows particular foods or is fading. That gives your prescriber something concrete when deciding whether and when to move up a step.

Ozempic® and Rybelsus® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.